Chinese scientists deploy AI platform to transform drug evaluation

Researchers in China have introduced an artificial intelligence platform that significantly accelerates the evaluation of medicines across the entire human genome, marking a major advance in drug discovery and chemical genomics. This is reported by Ahora San Juan, a partner of TV BRICS.

The system enables scientists to map interactions between drug molecules and all proteins encoded in the human genome at unprecedented speed.

Chemical genomics focuses on identifying compounds capable of interacting with disease-related proteins, many of which remain untapped by existing therapies. Traditional computational approaches face severe limitations due to the vast number of possible molecular interactions, making full-genome screening impractical. The new AI-based platform overcomes this challenge by accelerating the screening process by up to one million times, allowing genome-wide analysis to be carried out efficiently for the first time.

The platform works by converting protein–molecule interactions into mathematical representations, enabling the rapid evaluation of millions of combinations simultaneously. Since becoming publicly available in 2025, the platform has been adopted by more than a thousand researchers worldwide, supporting tens of thousands of large-scale analyses.

Experts note that the technology not only shortens the timeline for identifying potential medicines but also expands the range of compounds that can be explored. By revealing previously inaccessible therapeutic targets, the platform is expected to contribute to the development of new treatments for diseases that currently lack effective drugs.

Photo: metamorworks / iStock